Implementation of allogeneic hematopoietic stem cell transplantation from unrelated donors from Russian and foreign registries

Introduction. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a standard treatment for many patients with hematological malignancies. Over the past 20 years, an increase in transplantation activity has been noted throughout the world. About 50 % of all allo-HSCT are transplanted from unrelated donors.

Aim: to present the dynamics and stages of the development of unrelated donation using the example of one transplant center.

Materials and methods. This study analyzed Allo-HSCT performed from 2009 to March 2019 at the National Research Center for Hematology (NRCH). The work of the unrelated donor recruiting group and the tissue typing laboratory was analyzed for this period. 107 patient requests for unrelated donor search were dissected to identify search failures. The parameters of 206 unrelated donors were estimated depending on the register (Russian Federation/foreign).

Results. The number of allo-HSCTs did not exceed more than 20 per year, in 2009–2011. Since 2012, the number of alloHSCT significantly increased when the possibility for searching for unrelated donors abroad as well as in the Russian Federation (RF) databases appeared. During this time an increase by more than 50 % was noted in the number of allo-HSCTs. Allo-HSCs from unrelated donors of the Russian Federation make up 30–40 % of all unrelated allo-HSCs. 16 % of potential donors of hematopoietic stem cells included in the NRCH registry are donors of the human blood components. Despite the increasing number of unrelated donors in international and RF databases, 12 % of patients did not find a compatible donor in any of the registers, due to a rare combination of HLA genes. It was revealed that among donors from the RF from whom alloHSCT was performed, there was not a significant prevalence of men, compared to the foreign registry, 50.7 % and 66.7 %, respectively, despite the preference of donor-male by doctors. The 5-year overall survival in patients with acute leukemia in the first complete remission, depending on the performance of allo-HSCT from a donor from the RF or foreign registers, are comparable, 40 % and 39.5 %, respectively.

Conclusion. The number of allo-HSCT has increased 5 times over the past 10 years largely due to the development of unrelated donation: 30–40 % of allo-HSC transplants received from unrelated donors were performed from donors from the United database of the Russian Federation. The 5-year overall survival of these patients is comparable with the results of the overall survival patients who received transplants from donors from foreign registers.

1. Savchenko V.G., Lubimova L.S., Parovichnikova E.N. et al. Allogenic and autologus hematopoietic stem cells transplantation in patients with acute leukemia (results of 20 years old experience). Terapevticheskiy arkhiv. 2007; 7: 30–5 (In Russian).

2. Rumyancev A.G., Maschan A.A. Hematopoietic stem cells transplantation in children. Moscow: Medical information agency; 2003. 912 p. (In Russian).

3. Afanas’ev B.V., Zubarovskaya L.S. The role of hematopoietic stem cells transplantation in adults with acute leukemia. Onkogematologiya. 2006; 1–2: 70–85 (In Russian).

4. Apperley J., Carreras E., Gluckman E., editor. The 2012 revised edition of the EBMT-ESH Handbook on Haematopoietic Stem Cell Transplantation. 6th ed. forum service editore; 2012. 683 p.

5. Passweg J.R., Baldomero H., Bader P. et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017; 52(6): 811–7. DOI: 10.1038/bmt.2017.34.

6. Alyanskii A.L., Makarenko O.A., Ivanova N.E. et al. Development of donor bone marrow registry in Russian Federation: experience of Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation. Russkiy Jurnal detskoy Gematologii i onkologii. 2016; 3(2): 68–74. DOI: 10.17650/2311-1267-2016-3-2-68-74 (In Russian).

7. Okseinot G.K., Nikitina S.Yu., Агеева L.I. et al. Healthcare in Russia 2017. Stat. sb./Rosstat. Moscow; 2017. 170 p. (In Russian).

8. Rosenmayr A., Pointner-Prager M., Mitterschiffthaler A. et al. What are a patient’s current chances of fi nding a matched unrelated donor? Twenty years’ central search experience in a small country. Bone Marrow Transplant. 2012; 47(2):172–80. DOI: 10.1038/bmt.2011.67.

9. Mendeleeva L.P., Savchenko V.G., Parovichnikova E.N. et al. Analysis of transplantation activity in the Russian Federation for 2018 (report of the interregional register). Gematologiya I Transfusiologiya. 2020, 65(1)(S1): 180. (In Russian).

10. Passweg J.R., Baldomero H., Bader P. et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2018; 53(9): 1139–48. DOI: 10.1038/s41409-018-0153-1.

11. Khamaganova E.G., Kuzminova E.P., Abdrakhimova A.R. et al. Genetic distances of HLA genes between donors of hematopoietic stem cells of the register National research center for hematology of Russian and world populations. Transfusiologiya. 2018; 19(1): 13–26. (In Russian).

12. Müller C.R., Ehninger G., Goldmann S.F. Gene and haplotype frequencies for the loci HLA-A, HLA-B, and HLA-DR based on over 13,000 German blood donors. Hum Immunol. 2003; 64(1): 137–51. DOI: 10.1016/S0198-8859(02)00706-1.

13. Furst D., Muller C., Vucinic V. et al. High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis. Blood. 2013; 122(18): 3220–9. DOI: 10.1182/blood-2013-02-482547.

14. Morishima Y., Kawase T., Malkki M. et al. Signifi cance of ethnicity in the risk of acute graft-versus-Host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 19(8): 1197–203. DOI: 10.1016/j.bbmt.2013.05.020.

15. Savchenko V.G. Protokols of allogenic hematopoietic stem cells transplantation. Мoscow: Practika; 2020. 320 p. (In Russian).

16. Khamaganova E.G., Kuzmina L.A. Assessment of HLA-compatibility and requirements for HLA-typing of patient and donor in allogeneic hematopoietic stem cell transplantation. Gematologiya i Transfusiologiya. 2019; 64 (2): 175–87 DOI: 10.35754/0234-5730-2019-64-2-175-187. (In Russian).

17. Biderman B. V., Yakutik I.A., Khamaganova E.G. et al. Identifi cation of a novel allele HLA-С*12:138 in Russian patient by haplotype-specifi c sequence-based typing. Tissue Antigens. 2015; 85(6): 513–4. DOI: 10.1111/tan.12549.

18. Carreras E., Dufour C., Mohty M. et al., editors. The EBMT Handbook. Cham: Springer International Publishing; 2019. DOI: 10.1007/978-3-030-02278-5.

19. Passweg J.R., Baldomero H., Peters C. et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant. 2014; 49(6): 744–50. DOI: 10.1038/bmt.2014.55.

20. Saito H., Ito M., Kato S. et al. The Japan Marrow Donor Program, 25 years of experience in achieving 20,000 bone marrow transplantations: Organization structure, activity, and fi nancial basis. Bone Marrow Transplant. 2018; 53(5): 609–16. DOI: 10.1038/s41409-017-0084-2.

21. Gragert L., Eapen M., Williams E. et al. HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry. N Engl J Med. 2014; 371(4): 339– 48. DOI: 10.1056/NEJMsa1311707.

22. Nakasone H., Remberger M., Tian L. et al. Risks and benefi ts of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy. Haematologica. 2015; 100(11): 1477–85. DOI: 10.3324/haematol.2015.125294.

23. Makarenko O.A., Alyanskii A.L., Ivanova N.E. et al. The effecasy of the searching of unrelated donor of hematopoietic stem cells by using the Russian search system Bone Marrow Donor Search: experience of the Scientifi c Research Institute of Pediatric Oncology, Hematology and Transplantology R.M. Gorbacheva. Klini cheskaya onkogematologiya. 2017; 10(1): 39–4 DOI: 10.21320/2500- 2139-2017-10-1-39-44. (In Russian).